Skip to main navigation
Skip to content
  • Contact
  • Twitter
  • Linkedin
gbt
  • About
    • Our Company
    • Leadership
    • Board of Directors
    • Contact Us
    • Careers
  • Our Commitment
    • Patients & Advocacy
    • GBT’s Supported Conferences
    • COVID-19 Information and Resources
    • Corporate Giving
    • The GBT Foundation
    • Expanded Access
    • Environmental, Social and Governance
  • Research
    • Sickle Cell Disease
    • Pipeline
    • Externally Sponsored Research (ESR)
    • Partnerships
    • Publications
  • Our Medicine
  • Investors & Media
    • Company Summary
    • Media Resources
    • Press Releases
    • Events & Presentations
    • Quarterly Results
    • Analyst Coverage
    • Stock Information
    • SEC Filings
    • Governance
    • Investor FAQs
  • Careers
    • Jobs
  • Contact Us
  • Twitter
  • LinkedIn
Investors & Media
  • Company Summary
  • Media Resources
  • Press Releases
  • Events & Presentations
  • Quarterly Results
  • Analyst Coverage
  • Stock Information
  • SEC Filings
  • Governance
  • Investor FAQs
  • Print Page
  • RSS Feeds
  • Email Alerts
  • IR Contact

Media Resources

Media Resources

Recent Press Releases and Statements
Date Title
Aug 08, 2022
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
Aug 04, 2022
GBT Announces New Employment Inducement Grants
Aug 03, 2022
GBT Announces Participation at the Wedbush PacGrow Healthcare Conference
Jul 29, 2022
GBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022
Jul 26, 2022
MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
Media Resources
Product Image - Oxbryta® (voxelotor) Tablets and Tablets for Oral Suspension
Fact Sheet - Oxbryta® (voxelotor) Tablets and Tablets for Oral Suspension
Addressing Inequalities in Healthcare: Spotlight on SCD in Europe
Overview of the Sickle Cell Disease Environment in Select European Countries
Pediatric to Adult Care Transition Infographic
Sickle Cell Disease Infographic
High Resolution Corporate Logo
The GBT Foundation Fact Sheet

Media and Investor Contact

Steven Immergut
SVP, Head of Corporate Communications and Investor Relations
650-410-3258
simmergut@gbt.com

  • Print Page
  • RSS Feeds
  • Email Alerts
  • IR Contact
gbt

Copyright 2022
Global Blood Therapeutics, Inc.

  • Privacy Policy
  • Online Tracking Opt-Out Guide
  • Terms of use
  • Community Guidelines

P-VOX-US-00501

  • About
    • Our Company
    • Leadership
    • Board of Directors
    • Contact Us
    • Careers
  • Our Commitment
    • Patients & Advocacy
    • GBT’s Supported Conferences
    • COVID-19 Information and Resources
    • Corporate Giving
    • The GBT Foundation
    • Expanded Access
    • Environmental, Social and Governance
  • Research
    • Sickle Cell Disease
    • Pipeline
    • Externally Sponsored Research (ESR)
    • Partnerships
    • Publications
  • Our Medicine
  • Investors & Media
    • Company Summary
    • Media Resources
    • Press Releases
    • Events & Presentations
    • Quarterly Results
    • Analyst Coverage
    • Stock Information
    • SEC Filings
    • Governance
    • Investor FAQs
  • Careers
    • Jobs
  • Contact Us
  • Twitter
  • LinkedIn
This site uses cookies to give you the best online experience. Learn more, including how to disable certain cookies on our Privacy Page. Accept
Privacy & Cookies Policy